MetaCap

Vericel Corporation (VCEL)

NASDAQ: VCELHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

57.52-0.74 (-1.27%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

VCEL stock chart

Technical analysis

Key statistics

All statistics
52-week range
28.95 – 59.75
Day range
57.33 – 59.49
Volume / Avg
582.32K / 664.34K
Beta
—

52-week range

$28.95$59.75

VCEL stock today

On Nov 20, VCEL ended the session at $57.52, shedding $0.74 (1.27%), versus the S&P 500's 3.70% decline. At this level, VCEL sits near the top of its 52-week range of $28.95 to $59.75: 3.7% below the high, set on Nov 11, 2026 and 98.7% above the low. VCEL is up 59.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 45.3%.

Vericel trades at 89.9x its trailing twelve-month earnings per share of $0.64. Its forward P/E of 61.1x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Vericel

Company profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Dominick C. Colangelo Esq.
Headquarters
Burlington, MA
Employees
398
Website
vcel.com

Financial highlights

Full financials

In fiscal 2025, Vericel generated $276.3 million in revenue, up 16.5% from fiscal 2024, its 12th consecutive year of revenue growth. Net income was $16.5 million (+59.4% year over year), for a net margin of 6.0% versus a median of -1.6% in the prior 5 years. Gross margin was 74.4% (up from 72.6%) and operating margin 4.0%.

Vericel annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$276.26M$237.22M$197.52M$164.37M$156.18M
Growth+16.45%+20.10%+20.17%+5.24%+25.77%
Net income$16.52M$10.36M$-3.18M$-16.71M$-7.47M
EPS (diluted)$0.32$0.20$-0.07$-0.35$-0.16

Analyst forecast

Forecast

Consensus (8 analysts)

strong_buy

Avg. price target

$65.43+13.75%

  • Strong buy 0
  • Buy 7
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $60.00High $75.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$0.27 vs $0.02
Surprise
+1250.00%

VCEL news

All VCEL news

Vericel peers

Health Care sector
VCEL peer companies
CompanyPrice% ChgMarket capCompare
DNLIDenali Therapeutics Inc.18.45+1.37%$2.96Bvs VCEL
ADMAADMA Biologics Inc13.17-1.27%$2.92Bvs VCEL
IOVAIovance Biotherapeutics Inc.6.90-5.61%$3.19Bvs VCEL
RLAYRelay Therapeutics Inc.16.12+1.32%$3.56Bvs VCEL
TARSTarsus Pharmaceuticals Inc.73.01-6.00%$3.60Bvs VCEL
BEAMBeam Therapeutics Inc.20.90-0.19%$2.16Bvs VCEL
CRSPCRISPR Therapeutics AG39.10+0.44%$3.79Bvs VCEL
BCRXBioCryst Pharmaceuticals Inc.7.22-1.37%$1.86Bvs VCEL

Indexes, lists and sector

Vericel stock FAQ

What is Vericel's stock price today?

VCEL last traded at $57.52 as of Nov 20, 4:00 PM EST, down 1.27% on the day. Prices are delayed at least 15 minutes.

Does Vericel pay a dividend?

No. Vericel does not currently pay a regular cash dividend.

What is VCEL's P/E ratio?

VCEL trades at a trailing P/E ratio of 89.88 and a forward P/E of 61.06.

Who is Vericel's CEO?

Mr. Dominick C. Colangelo Esq. is the chief executive officer of Vericel Corporation, which has about 398 employees.

Has VCEL ever split its stock?

Yes. The most recent VCEL stock split was a 1-for-20 split on Oct 16, 2013, one of 2 splits on record.

What is the VCEL 52-week high?

The 52-week high for VCEL is $59.75 and the 52-week low is $28.95. The stock is currently 3.7% below its high.

Compare VCEL